Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768284 | 0.96 | PLA2G10 (0.38) | PLA2G10PLA2G2ACA1DUTCA2 | |
| SCHEMBL23768524 | 0.93 | CA1 (0.36) | PLA2G10PLA2G2ACA1DUTCA2 | |
| SCHEMBL19543590 | 0.82 | DUT (0.36) | PLA2G10PLA2G2ADUT | |
| SCHEMBL19543582 | 0.81 | RAD52 (0.34) | DUTHTTKMT2A | |
| SCHEMBL29132544 | 0.81 | L3MBTL1 (0.41) | DUTTSHRNAAAKMT2A | |
| SCHEMBL31410816 | 0.80 | DUT (0.35) | DUT | |
| SCHEMBL2560206 | 0.80 | L3MBTL1 (0.47) | DUTTSHRNAAAKMT2A | |
| SCHEMBL19543584 | 0.79 | DUT (0.32) | DUT | |
| SCHEMBL21398845 | 0.79 | TSHR (0.42) | PLA2G10PLA2G2ACA1CA2CA7 | |
| SCHEMBL21398746 | 0.79 | TSHR (0.42) | PLA2G10PLA2G2ACA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | TOPIKOS PHARMACEUTICALS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253607-A1 | ORGANOSILANES FOR THE TREATMENT OF INFECTIONS | ASNS, ACMSD, ARG1 | PLA2G10 4031/4885PLA2G2A 4542/4885CA1 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.